Evaluation of the Antiviral Nucleoside Lobucavir Against Woodchuck Hepatitis Virus (WHV) in Chronically Infected Woodchucks
April 11, 1997
I. Medina, et al
Lobucavir has activity against human hepatitis B virus (HBV) (EC50 = 2.5 uM in HepG2.2.15 cells). This poster presented the efficacy of Lobucavir in woodchuck model. Animals chronically infected with hepatitis B (WHV) were dosed orally with Lobucavir (10 or 20 mg/kg daily). Serum levels of WHV DNA were generally reduced to below limit of detection (about 2 log reduction) after 1-2 weeks of treatment and returned to base-line within 1-2 weeks after therapy. Lower doses were less effective.
Although Lobucavir was effective in this model, its efficacy and potency is markedly less than that of BMS-200475 (see #32 in this report). However, BMS-200475 is only starting phase I clinical trials whereas a Lobucavir trial in hepatitis patients is already ongoing.
This article was provided by TheBodyPRO. It is a part of the publication The 10th Annual International Society For Antiviral Research Conference.